LETTERS TO THE EDITOR

Evidence against an autoimmune aetiology for inflammatory bowel diseases

Sir,—The leading article that appeared in Gut1 raised the question of whether inflammatory bowel diseases (IBD) are autoimmune disorders. Since IBD do not fulfil all criteria for classification as autoimmune disorders, analogies between the two groups of diseases may be of interest.

Circulating interferon (IFN) is commonly detected in patients with autoimmune disorders (the so called ‘autoimmune–IFN’) as well as in patients with AIDS, correlating with disease progression.2,3 Although circulating IFN is not included in the list of criteria suggestive of autoimmune disorders, the presence of acid-labile IFN-α is believed to reflect continuing autoimmune reactions.4

We tested 51 sera from patients with either ulcerative colitis or Crohn’s disease for the presence of IFN using a sensitive bioassay. For comparison, 41 sera of HIV infected patients were also tested. No IFN was detected in the serum samples from the IBD group while 10 sera from the HIV infected patients were positive for IFN with titres ranging from 5 to 200 IU/ml. This IFN was acid-labile, and characterised as α-type by sensitivity to neutralisation with a specific antiserum. IBD sera were also tested for the presence of neutralising antibodies to IFN α or γ and no IFN antibodies were found in IBD sera. Thus, although T cells and macrophages are activated in Crohn’s disease and IFN-γ is actively released in the diseased gut,5 no circulating autoimmune IFN can be detected in these patients. These observations provide new evidence against an autoimmune aetiology for IBD.

FRANCESCO PALLONE
Clinica Medica 2
Università La Sapienza
Viale de’ Polacchi 100/161
Roma, Italy

STEFANO FAIS
Cattedra di Gastroenterologia
Clinica Medica 11
Polisoclinico Umberto 1
Roma, Italy

MARIA R CAPOBIANCHI
Istituto di Virologia
Università di Roma
La Sapienza
Roma, Italy

Correspondence to: Professor F Pallone.

References

3 Eyster ME, Goedert JJ, Poon MC, Preble OT. Acid-labile alpha-interferon. A possible preclini-
4 Preble OT, Black RJ, Friedman RM, Klippel JH, Vileik J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leucocy-
8 Mahida YR, Patel S, Wu K, Jewell DP. Interleukin 2 receptor expression by macrophages in inflam-

Macrophage subpopulations in pouchitis

Sir,—We read with great interest the article by De Silva et al (Gut 1991; 32: 1160–5) on lymphocytes and macrophage subpopulations in pelvic ileal pouches. We have recently performed a similar study characterising immunohistochemically macrophages subsets in ileal pouches with and without pouchitis. Pouch biopsy specimens were stained with monoclonal antibodies (RFDF-1 dendritic cells, RFDF-7 mature macrophages, RFDF-9 epithelioid cells, and tingible body macrophages) using the immunoperoxidase technique.

In agreement with the results of De Silva et al, we found a significantly higher proportion of RFDF9+ cells in patients with pouchitis (n=10) than in uninflamed pouches (n=20) or normal ileum (n=10), while there were no differences between the three groups in the number of cells positive for the other macrophage markers. Since an increased presence of RFDF9+ macrophages has been shown in inflammatory bowel disease, but not in infec-
tious colitis,1 we agree with the authors that the presence of this histochemical pattern in pouchitis may suggest pathogenetic mecha-
nisms similar to those of original ulcerative colitis.

Macrophages play a major role in mediating and regulating inflammatory and immunolog- ical responses in gut mucosa through a number of specialised functions, including antigen presentation and secretion of mediators. The increased phenotypic heterogeneity of macrophages may be therefore caused by the persistent stimulation and activation of these cells in an inflamed mucosa.2

This hypothesis is further supported by our recent observation (unpublished data) of a significantly higher interleukin-1β mucosal content in pouch biopsy specimens from pouchitis compared with specimens from uninflamed pouches, as in the case of ulcerative colitis.1

P GIONCHETTI
M CAMPIERI
A BELLUZZI
G M PAGANELLI
M TAMPIERI
E BERTELINELLI
C BRIGNOLA
M G POGGIOLI
M MIGLIOLI
G GOZZETTI
L BARBARA
Instituto di Clinica Medica e Gastroenterologia, and Istituto di Clinica Chirurgica II, Università di Bologna, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy

NOTES

Sir Francis Avery Jones BSG Research Award 1993

Applications are invited by the Education Committee of the British Society of Gastro-
enterology who will recommend to Council the recipient of the 1993 Award. Applications (15 copies) should include:

(1) A manuscript (2 A4 pages only) descri-
bing the work conducted.

(2) A bibliography of relevant personal publications.

(3) An outline of the proposed content of the lecture, including title.

(4) A written statement confirming that all or a substantial part of the work has been personally conducted in the United Kingdom or Eire.

The award consists of a medal and a £100 prize. Entrants must be 40 years or less on 31 December 1993 but need not be a member of the BSG. The recipient will be required to deliver a 40 minute lecture at the Spring Meeting of the Society in 1993. Applications (15 copies) should be made to: The Honorary Secretary, BSG, 3 St Andrew’s Place, London NW1 4LB by 1 December 1992.

Dysphagia Research Society

The Inaugural Meeting of the Society will be held from 6–8 November 1992 in Milwaukee, Wisconsin. Further details and abstract forms from Dysphagia Research Society, Organising Office, c/o Reza Shaker MD, GI Section, VA Medical Center, 5000 W National Avenue, Milwaukee, Wisconsin, 53295 USA. Tel: 414 384 2004 ext 6943; fax: 414 384 8480.